<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T02:47:26Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14990" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14990</identifier><datestamp>2026-10-18T21:14:26Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance</dc:title><dc:creator>Ferroudj, Sana</dc:creator><dc:creator>Yildiz, Gokhan</dc:creator><dc:creator>Bouras, Mourad</dc:creator><dc:creator>Iscan, Evin</dc:creator><dc:creator>Ekin, Umut</dc:creator><dc:creator>Ozturk, Mehmet</dc:creator><dc:subject>BRCA1</dc:subject><dc:subject>chemosensitization</dc:subject><dc:subject>DSB DNA repair</dc:subject><dc:subject>Fanconi anemia</dc:subject><dc:subject>hepatocellular cancer</dc:subject><dc:subject>interstrand cross-linker drugs</dc:subject><dc:subject>BRCA1 protein</dc:subject><dc:subject>cisplatin</dc:subject><dc:subject>melphalan</dc:subject><dc:subject>mitomycin</dc:subject><dc:subject>small interfering RNA</dc:subject><dc:subject>Article</dc:subject><dc:subject>cell cycle</dc:subject><dc:subject>cell viability</dc:subject><dc:subject>controlled study</dc:subject><dc:subject>DNA repair</dc:subject><dc:subject>double stranded DNA break</dc:subject><dc:subject>down regulation</dc:subject><dc:subject>drug resistance</dc:subject><dc:subject>flow cytometry</dc:subject><dc:subject>G2 phase cell cycle checkpoint</dc:subject><dc:subject>gene expression regulation</dc:subject><dc:subject>HepG2 cell line</dc:subject><dc:subject>human</dc:subject><dc:subject>human cell</dc:subject><dc:subject>liver cell carcinoma</dc:subject><dc:subject>microarray analysis</dc:subject><dc:subject>priority journal</dc:subject><dc:subject>protein cross linking</dc:subject><dc:subject>protein expression</dc:subject><dc:description>Aim: To investigate the expression of DNA repair genes and the impact of the breast cancer 1, early onset (BRCA1) protein on chemoresistance of hepatocellular carcinoma (HCC). Methods: Microarray gene expression datasets were analyzed using the gene set enrichment analysis method. BRCA1 protein was tested by Western blotting. Response of HCC cells to interstrand cross-links was investigated by cell viability assay following exposure to mitomycin C, cisplatin, and melphalan. Effects of BRCA1 ectopic expression were studied in HepG2 cells with BRCA1-expression plasmids. Effects of BRCA1 downregulation were studied in SNU449 cells with BRCA1-specific siRNAs. Response of transfected SNU449 cells to mitomycin C was analyzed by cell viability tests and cell cycle analysis using flow cytometry. Results: Expression of Fanconi anemia and double-stranded DNA break repair genes was significantly upregulated in HCC tumors. This upregulation displayed a gradual amplification during tumor progression. BRCA1 and BRCA2 genes were among consistently upregulated genes. Epithelial-like HCC cells had low BRCA1 expression and low chemoresistance, whereas mesenchymal-like HCC cells had high BRCA1 expression and increased chemoresistance. Ectopic expression of BRCA1 increased the chemoresistance of epithelial-like HepG2 cells. Conversely, BRCA1 knockdown chemosensitized mesenchymal-like SNU449 cells. Chemosensitization of SNU449 cells was due to cell cycle arrest at 4N stage. Conclusion: Increased expression of Fanconi anemia and double-stranded DNA repair genes such as BRCA1 is a novel mechanism of HCC chemoresistance. However, functional inactivation of BRCA1 expression is sufficient to reverse such chemoresistance. © 2016 The Japan Society of Hepatology</dc:description><dc:publisher>Blackwell Publishing Ltd</dc:publisher><dc:date>2016</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/14990</dc:identifier><dc:identifier>https://doi.org/10.1111/hepr.12675</dc:identifier><dc:identifier>1386-6346</dc:identifier><dc:language>en</dc:language><dc:relation>Hepatology Research</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14990</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>